claim: 68 per cent of patients hospitalized for severe covid-19, who were treated with compassionate-use remdesivir, without clinical improvement
evidence_1: although data from several ongoing randomized, controlled trials will soon provide more informative evidence regarding the safety and efficacy of remdesivir for covid-19, the outcomes observed in this compassionate-use program are the best currently available data.